Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ERSP gives Swiss Labs go-ahead with changes

This article was originally published in The Tan Sheet

Executive Summary

The Electronic Retailing Self-Regulation Program gives thumbs up to Swiss Labs for substantiating most claims for its Arthi-Zen Relief Dietary Supplement, but asks the firm to modify certain statements. ERSP says July 9 the marketer's clinical study supported general efficacy claims for the reduction of joint and muscle discomfort, but asks the firm to remove mention of "clinical studies" because there is only one. The group also asked Swiss Labs to modify the "immediate" relief claim because the study suggested most saw improvement after four days, and to modify the context of the claim "24-Hour Joint Relief" to explain that users "can experience relief for up to 24 hours in between dosages." Swiss Labs said it will comply. ERSP reviewed the Kankakee, Ill.-based firm's ads in ongoing monitoring

You may also be interested in...



FDA Grant Establishes Complex Generics Center To Increase Access

Complex active ingredients, formulations, routes of delivery, and drug-device combination products are to receive greater attention as part of attempts to facilitate competition after the US FDA awarded a $5m grant to establish a dedicated research center.

What’s Next? Five Things To Look Out For In October

In October, the period during which Mylan may complete its merger with Upjohn will begin, while the FDA will begin holding monthly stakeholder meetings ahead of the third iteration of the Generic Drug User Fee Amendments program, also known as GDUFA III.

BioIndustry Association Slams New UK Guidance On Batch Testing

The UK life sciences trade group says the “ill-considered” guidance will result in duplicative and costly repetition and dent industry’s confidence in the government’s competence.

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel